David Muller

MD-PhD | Urologist | Postdoc Wyatt-Lab @ResearchWyatt | @VanProstateCtr | #bladdercancer, #prostatecancer

[Gillian Vandekerkhove @G_Vandekerkhove]

New white paper alert! https://t.co/Q5g2Z7hG0l. In this open access piece, we cover personalized cancer management through clinical genomic testing, with a focus on prostate cancer (PCa). Here's a snapshot of what we discuss: (1/5)

[David Muller @D_C_Muller]

@Markuseckstein3 We're currently looking at the extent of alterations missed due to insufficiencies of current diagnostics, and just submitted an abstract to #AACRbladder24; hope to see you in Charlotte! 2/2

[David Muller @D_C_Muller]

@Markuseckstein3 Another important point to consider when choosing a test is its comprehensiveness. Does it just cover specific recurrent variants, or can it find rare variants and non-canonical fusion breakpoints? 1/2

[David Muller @D_C_Muller]

@ClemLeMagnen @Nature_NPJ @Michele_Garioni Congratulations on the great work!

[David Muller @D_C_Muller]

@JnsHerrmann @trwherrmann You're showing the patient's name in the video!

[Gillian Vandekerkhove @G_Vandekerkhove]

Thanks @Uromigos for highlighting our work on FGFR alterations in mUC ctDNA

@D_C_Muller @ResearchWyatt @JackVWBacon

[Peter Black @pcvblack]

Deadline for abstract submission June 15th. Don't miss the opportunity to present at IBCN - one of the best #bladdercancer meetings of the year. If you have never been, come check us out!

[Clémentine Le Magnen @ClemLeMagnen]

Big congrats to @Michele_Garioni from our group for winning one of the #SNSF Scientific Image Competition awards for his video/art of #bladdercancer patient-derived #organoids:
https://t.co/asi4kuLIiW
#SwissScienceImage

[Alex Wyatt @ResearchWyatt]

In our new paper in @CCR_AACR: plasma ctDNA% in pts with mCRPC after 4 wks of abi/enza tx inform on subsequent duration of response (outperforming clinical variables). Can on-treatment ctDNA changes guide an early treatment switch or intensification? https://t.co/IqAdiNwBNN

[Alex Wyatt @ResearchWyatt]

Here’s a paper from our team in @Nature_NPJ Precision Oncology, led by newly-minted PhD Dr. Elie Ritch (@SudomanX), using machine learning to classify prostate cancer ctDNA samples by DNA damage repair phenotype on the basis of mutational signatures. https://t.co/Wzb3IgSlBx

[Andrea Apolo, M.D. @apolo_andrea]

@G_Vandekerkhove beautifully discusses ctDNA to asses tumor heterogeneity in #BladderCancer @AmerUrological #JHU/AUA @HopkinsMedicine @hopkinskimmel @h_alahmadie

[David Muller @D_C_Muller]

@ClemLeMagnen @MicGarioni @UniSpitalBasel @DepBiomedicine Congratulations on the great work!

[Alex Wyatt @ResearchWyatt]

Does anyone know why there are seemingly no clinical reports of FGFR3 gatekeeper mutations (post-FGFRi) in advanced bladder cancer? Or could someone please point me towards the studies, if there are reports in the literature?

[David Muller @D_C_Muller]

@pcvblack @VanProstateCtr @UniSpitalBasel @LukasBubendorf @ResearchWyatt @ClemLeMagnen @rmorgan7_e @G_Vandekerkhove @MurthaAj @moritzreike Thanks to all who participated today. It was great to see how the groups clicked.

[Peter Black @pcvblack]

After a long hiatus very happy to host clinical and research fellows chez Black for a little Christmas gathering - very proud to be connected to all these #bladdercancer researchers and caregivers and their families!

[David Muller @D_C_Muller]

Shout out to Moritz Reike, @pcvblack, and all other contributors. Thank you! @IBCN1997 #bladdercancer

AddThis | Home https://t.co/1vnas6PF18

[Alex Wyatt @ResearchWyatt]

Big congrats to PhD student @MurthaAj presenting at #MAP2022 on results from our multi-year collaboration with @piet_ost team, studying intra-patient genomic complexity of treatment-naive de novo metastatic prostate cancer!